产品说明书
TTA-A2
 |
同义名 : | - |
| CAS号 : | 953778-63-7 | |
| 货号 : | A345511 | |
| 分子式 : | C20H21F3N2O2 | |
| 纯度 : | 98%+ | |
| 分子量 : | 378.388 | |
| MDL号 : | MFCD16628062 | |
| 存储条件： |
粉末 Sealed in dry,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(277.49 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | TTA-A2 is a potent, selective and orally active T-type voltage gated calcium channel antagonist that reduces the activation of PXR. TTA-A2 is equally effective on Cav3.1 (a1G) and Cav3.2 (a1H) channels, with IC50 values of 89% and 89% at -80 and -100 mV holding potentials, respectively. The IC50 values at -80 and -100 mV holding potentials were 89 nM and 92 nM, respectively. TTA-A2 can be used to study a variety of human neurological disorders, including sleep disorders and epilepsy[1][2].TTA-A2 exhibits high affinity in the α1I binding assay with an affinity of 1.2 nM, and has excellent selectivity for hERG potassium channels and L-type calcium channels (both with IC50 values greater than 10 μM)[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.64mL 0.53mL 0.26mL |
13.21mL 2.64mL 1.32mL |
26.43mL 5.29mL 2.64mL |
| 参考文献 |
|---|
|
[1]Thomas S Reger, et al.Pyridyl amides as potent inhibitors of T-type |